Fattori predittivi nelle biopsie prostatiche

Abstract

Prostate cancer (PCa) is a leading cause of morbidity and mortality in men, accounting for approximately 30% of all new cases of cancer and approximately 14% of cancer deaths. Despite considerable advances achieved in the ability to detect and treat PCa, there have not been significant corresponding decreases in PCa-related morbidity and mortality. Proper examination of prostate biopsy specimens by pathologists is critical in determining the type of treatment and predicting patient outcome. The goal is to tailor the therapeutic approach to the clinical, morphological and molecular features of each patient.

Neuroendocrine Differentiation in the Progression of Prostate Cancer: An Update on Recent Developments

“…This idea is supported by the fact that benign prostatic tissue contains low level of VEGF, whereas VEGF staining intensity correlates with Gleason grade. Complete androgen blockade for three months before surgery, decreased VEGF level and vascularisation, except in areas where cells are NE-like [55]. In radical prostatectomy samples, there is a correlation between NE differentiation and neovascularisation and both correlate with tumour grade and tumour stage.…”